Tag Archives: NASDAQ:SPPI

Spectrum Pharmaceuticals (SPPI) Receives a Buy from H.C. Wainwright

H.C. Wainwright analyst Edward White maintained a Buy rating on Spectrum Pharmaceuticals (SPPI – Research Report) today and set a price target of $13.00. The company’s shares closed last Monday at $3.93. According to TipRanks.com, White is a 5-star analyst

Spectrum Pharmaceuticals (SPPI) Gets a Buy Rating from H.C. Wainwright

H.C. Wainwright analyst Edward White reiterated a Buy rating on Spectrum Pharmaceuticals (SPPI – Research Report) today and set a price target of $13.00. The company’s shares closed last Monday at $2.95, close to its 52-week low of $1.74. According

B.Riley FBR Reaffirms Their Buy Rating on Spectrum Pharmaceuticals (SPPI)

B.Riley FBR analyst Mayank Mamtani reiterated a Buy rating on Spectrum Pharmaceuticals (SPPI – Research Report) today and set a price target of $8.00. The company’s shares closed last Monday at $3.29. According to TipRanks.com, Mamtani is a 5-star analyst

B.Riley FBR Thinks Spectrum Pharmaceuticals’ Stock is Going to Recover

In a report released today, Mayank Mamtani from B.Riley FBR reiterated a Buy rating on Spectrum Pharmaceuticals (SPPI – Research Report), with a price target of $8.00. The company’s shares closed last Friday at $2.81, close to its 52-week low

B.Riley FBR Sticks to Its Buy Rating for Spectrum Pharmaceuticals (SPPI)

In a report released today, Mayank Mamtani from B.Riley FBR reiterated a Buy rating on Spectrum Pharmaceuticals (SPPI – Research Report), with a price target of $8.00. The company’s shares closed last Monday at $2.86, close to its 52-week low

Analysts’ Top Healthcare Picks: Spectrum Pharmaceuticals (SPPI), Stoke Therapeutics Inc (STOK)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Spectrum Pharmaceuticals (SPPI – Research Report), Stoke Therapeutics Inc (STOK – Research Report) and Replimune Group Inc (REPL – Research Report) with